Maternal and perinatal outcomes among severe preeclampsia mothers treated with levetiracetam versus magnesium sulfate

Read full text Summarise with VIRAT
Authors: Poulomi Saha, Raju Gopal Saha, Kriti Gupta, Rajib Pal
Cited by: 0
References: 15

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Severe preeclampsia is a major contributor to maternal and neonatal morbidity and mortality worldwide. Magnesium sulfate is the gold standard for seizure prophylaxis, but its use is limited by the need for intensive monitoring and potential adverse effects. Levetiracetam has emerged as a potential alternative due to its favourable safety profile. This study aimed to compare the safety and efficacy of levetiracetam and magnesium sulfate in severe preeclampsia. Methods: A prospective observational study was conducted at a tertiary care hospital from June 2024 to December 2025 among 84 pregnant women with severe preeclampsia (>28 weeks gestation). Participants were equally divided into two groups: magnesium sulfate (n=42) and levetiracetam (n=42). Maternal outcomes (eclampsia, ICU admission, complications, hospital stay) and neonatal outcomes (birth weight, APGAR score, NICU admission) were recorded. Statistical analysis was performed using appropriate tests, with p

Fields of Study & Subjects

Pregnancy and preeclampsia studies Neurological Complications and Syndromes Neonatal and fetal brain pathology

Publication details

Journal / source
International Journal of Clinical Obstetrics and Gynaecology
Volume
10
Issue
2
Pages
580–584
Publication date
1 March 2026
Language
EN